These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Hoedemaker C; van Egmond S; Sinclair R Australas J Dermatol; 2007 Feb; 48(1):43-5. PubMed ID: 17222303 [TBL] [Abstract][Full Text] [Related]
26. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. Blume-Peytavi U; Kunte C; Krisp A; Garcia Bartels N; Ellwanger U; Hoffmann R J Dtsch Dermatol Ges; 2007 May; 5(5):391-5. PubMed ID: 17451383 [TBL] [Abstract][Full Text] [Related]
27. Finasteride treatment may not prevent telogen effluvium after minoxidil withdrawal. Tosti A; Iorizzo M; Vincenzi C Arch Dermatol; 2003 Sep; 139(9):1221-2. PubMed ID: 12975176 [No Abstract] [Full Text] [Related]
28. Topical minoxidil for baldness: a reappraisal. Med Lett Drugs Ther; 1994 Jan; 36(914):9-10. PubMed ID: 8277913 [No Abstract] [Full Text] [Related]
29. Topical minoxidil in the treatment of male pattern alopecia. Kvedar JC; Baden HP Pharmacotherapy; 1987; 7(6):191-7. PubMed ID: 3328164 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of oral minoxidil in the treatment of alopecia areata. Fiedler-Weiss VC; Rumsfield J; Buys CM; West DP; Wendrow A Arch Dermatol; 1987 Nov; 123(11):1488-90. PubMed ID: 3674909 [TBL] [Abstract][Full Text] [Related]
33. Treatment of female androgenetic alopecia with minoxidil 2%. Whiting DA; Jacobson C Int J Dermatol; 1992 Nov; 31(11):800-4. PubMed ID: 1428436 [TBL] [Abstract][Full Text] [Related]
34. A randomized trial of minoxidil in chemotherapy-induced alopecia. Duvic M; Lemak NA; Valero V; Hymes SR; Farmer KL; Hortobagyi GN; Trancik RJ; Bandstra BA; Compton LD J Am Acad Dermatol; 1996 Jul; 35(1):74-8. PubMed ID: 8682968 [TBL] [Abstract][Full Text] [Related]
35. An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia. Dhurat R; Chitallia J; May TW; Jayaraaman AM; Madhukara J; Anandan S; Vaidya P; Klenk A Skin Pharmacol Physiol; 2017; 30(6):298-305. PubMed ID: 29055953 [TBL] [Abstract][Full Text] [Related]
36. [Sensitization for external treatment with minoxidil]. van Joost T Ned Tijdschr Geneeskd; 1988 Jun; 132(25):1141-2. PubMed ID: 3398938 [No Abstract] [Full Text] [Related]
37. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Lucky AW; Piacquadio DJ; Ditre CM; Dunlap F; Kantor I; Pandya AG; Savin RC; Tharp MD J Am Acad Dermatol; 2004 Apr; 50(4):541-53. PubMed ID: 15034503 [TBL] [Abstract][Full Text] [Related]
38. Does topical minoxidil increase skin blood flow? A laser Doppler flowmetry study. de Boer EM; Bezemer PD; Bruynzeel DP; Nieboer C Acta Derm Venereol; 1988; 68(3):271-4. PubMed ID: 2455426 [TBL] [Abstract][Full Text] [Related]
39. [The therapy of androgenetic alopecia with minoxidil]. Bammel A; Stern R; Sterry W Dtsch Med Wochenschr; 1993 May; 118(21):787-9. PubMed ID: 8504714 [No Abstract] [Full Text] [Related]
40. Topical minoxidil in the treatment of androgenetic alopecia in women. Olsen EA Cutis; 1991 Sep; 48(3):243-8. PubMed ID: 1935254 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]